Circulating cancer stem cell (CCSC)MarkerBreast cancer is one ofthe most common types of cancer in women worldwide. Recent studies have provided strong support for the cancer stem cell (CSC) hypothesis, which suggests that many cancers, including breast cancer, are driven by a subpopulation of ...
These patients are commonly described as having androgen-independent, hormone-resistant, or castration-resistant prostate cancer. For more information on the intended use and limitations for the CELLSEARCH® Circulating Tumor Cell Test, please refer to the Instructions for Use which can be found at ...
they have a metastatic potential that has been estimated to be 23 to 50 times greater than that of their single-cell counterparts [21]. In addition,
such as non-small-cell lung cancer (NSCLC) patients, it was even found that the quantity of EpCAM-negative CTCs was significantly larger than EpCAM
The predictive value of a test for a given clinical outcome (for example, in cancer, a primary tumour or metastasis will develop in a patient with a positive test): a test identifies the clinical status of a patient. Dielectrophoresis
Circulating cell-free DNA (cfDNA) has recently been recognized as a resource for biomarkers of cancer progression, treatment response, and drug resistance. However, few have demonstrated the usefulness of cfDNA for early detection of cancer. Although abe
Epidermal growth factor receptor (EGFR) mutation is a reliable and sensitive biomarker for EGFR-TKI therapy in non-small-cell lung cancer (NSCLC). However, detection of EGFR mutation in tissues has obvious limitations. Circulating free DNA (cfDNA) has been reported as an alternative approach for...
- 《European Journal of Cancer》 被引量: 41发表: 2012年 Total serum DNA and DNA integrity: diagnostic value in patients with hepatitis B virus-related hepatocellular carcinoma. This study aimed to test the diagnostic utility of the total serum cell-free DNA (cfDNA) and DNA integrity index ...
Circulating tumour cells (CTCs) can be captured from a simple blood test and their molecular characterization can provide vital insights into tumour heterogeneity Advances in single-cell genomic profiling have enhanced the ability to interrogate CTCs for 'actionable' aberrations and emerging resistant subc...
which include cell-free DNA (for example, circulating tumour DNA, cell-free mitochondrial DNA and cell-free viral DNA) and cell-free RNA, applying modern molecular biology-based technologies and machine learning techniques closely allied to the underlying biology of cancer. Taken together, these app...